

Jesper Jensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8532256/publications.pdf>

Version: 2024-02-01

18
papers

394
citations

1163117

8
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

430
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	3.9	17
2	Reply. <i>JACC: Heart Failure</i> , 2022, 10, 70-71.	4.1	0
3	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). <i>Cardiovascular Diabetology</i> , 2022, 21, 34.	6.8	10
4	Sodium-glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, . .	2.5	1
5	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. <i>American Heart Journal</i> , 2022, 250, 57-57.	2.7	1
6	Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes. <i>Scandinavian Cardiovascular Journal</i> , 2022, 56, 256-263.	1.2	0
7	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 106-116.	11.4	80
8	Fluid volume regulation in patients with heart failure – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 258.	11.4	0
9	Response to Patoulias et al. letter regarding article “Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial”. <i>American Heart Journal</i> , 2021, 236, 106.	2.7	0
10	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). <i>Circulation</i> , 2021, 143, 2208-2210.	1.6	8
11	Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 836.	6.1	95
12	Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 824-835.	4.1	4
13	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. <i>Cardiovascular Diabetology</i> , 2020, 19, 180.	6.8	7
14	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. <i>American Heart Journal</i> , 2020, 228, 47-56.	2.7	61
15	Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2740-2751.	2.8	57
16	Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). <i>Trials</i> , 2019, 20, 374.	1.6	35
17	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 736-740.	4.4	16
18	Exercise-induced left bundle branch block – A case report with stress-echocardiographic assessment. <i>Journal of Electrocardiology</i> , 2018, 51, 508-510.	0.9	2